- IDE892 is a potent and selective MTA-cooperative PRMT5
inhibitor with favorable ADME properties; demonstrating robust MTAP
deletion-specific pathway suppression and highly durable antitumor
activity in combination with IDE397
- IND-enabling studies ongoing and targeting IND-filing for
IDE892 in mid-2025
SOUTH
SAN FRANCISCO, Calif., Dec. 9, 2024
/PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a
precision medicine oncology company committed to the discovery and
development of targeted therapeutics, today announced development
candidate nomination of IDE892, a potential best-in-class
MTA-cooperative PMRT5 inhibitor.
"We continue to expand our precision medicine oncology pipeline
and are excited to nominate our 7th development
candidate in IDE892, a potential best-in-class MTA-cooperative
PMRT5 inhibitor. IDE892 advances our strategic objective to enable
a wholly owned combination between the PRMT5 and MAT2A mechanisms,
to deliver potentially greater efficacy in MTAP-deletion solids
tumors through this rational combination approach," said
Yujiro S. Hata, President and Chief
Executive Officer of IDEAYA Biosciences. "Following extensive
structure-based design and lead optimization, we have achieved our
target product profile for the PRMT5 program with IDE892, including
favorable potency, selectivity, and synergistic combination
potential with MAT2A inhibitor IDE397," said Michael White, Ph.D., Chief Scientific Officer,
IDEAYA Biosciences.
IDE892 was discovered through IDEAYA's iterative physics-based
ligand design and optimization platform, and is a highly potent and
selective MTA-cooperative PRMT5 inhibitor with best-in-class
potential and favorable drug-like properties. IDE892 has
demonstrated exceptionally selective antiproliferative activity in
MTAP-deleted tumor cell models and durable complete responses in
combination with MAT2A inhibitor IDE397 in challenging
MTAP-deletion preclinical models. IND-enabling studies for IDE892
are ongoing to support an Investigational New Drug (IND) filing to
the U.S. Food and Drug Administration (FDA) in mid-2025, subject to
satisfactory completion of ongoing preclinical and IND-enabling
studies.
About IDEAYA Biosciences
IDEAYA is a precision
medicine oncology company committed to the discovery and
development of targeted therapeutics for patient populations
selected using molecular diagnostics. IDEAYA's approach integrates
capabilities in identifying and validating translational biomarkers
with drug discovery to select patient populations most likely to
benefit from its targeted therapies. IDEAYA is applying its
research and drug discovery capabilities to synthetic lethality –
which represents an emerging class of precision medicine
targets.
Forward-Looking Statements
This press release contains
forward-looking statements, including, but not limited to,
statements related to (i) the timing of an IND filing with the US
FDA and (ii) the potential efficacy, safety and therapeutic
benefits of IDEAYA's PRMT5 as a monotherapy and in combination with
MAT2A mechanisms, including the MAT2A inhibitor IDE397. Such
forward-looking statements involve substantial risks and
uncertainties that could cause IDEAYA's preclinical and clinical
development programs, future results, performance or achievements
to differ significantly from those expressed or implied by the
forward-looking statements. Such risks and uncertainties include,
among others, the uncertainties inherent in the drug development
process, including IDEAYA's programs' early stage of development,
the process of designing and conducting preclinical and clinical
trials, the regulatory approval processes, the timing of regulatory
filings, the challenges associated with manufacturing drug
products, IDEAYA's ability to successfully establish, protect and
defend its intellectual property, and other matters that could
affect the sufficiency of existing cash to fund operations. IDEAYA
undertakes no obligation to update or revise any forward-looking
statements. For a further description of the risks and
uncertainties that could cause actual results to differ from those
expressed in these forward-looking statements, as well as risks
relating to the business of IDEAYA in general, see IDEAYA's Annual
Report on Form 10-K dated February 20,
2024 and any current and periodic reports filed with the
U.S. Securities and Exchange Commission.
Investor and Media Contact
IDEAYA Biosciences
Andres Ruiz Briseno
SVP, Head of Finance and Investor Relations
investor@ideayabio.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ideaya-biosciences-announces-development-candidate-nomination-of-ide892-a-potential-best-in-class-mta-cooperative-prmt5-inhibitor-302325328.html
SOURCE IDEAYA Biosciences, Inc.
